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http://www.biomedcentral.com/1471-2164/15/1165RESEARCH ARTICLE Open AccessProteomics of muscle chronological ageing in
post-menopausal women
Marine Gueugneau1,2,7, Cécile Coudy-Gandilhon1,2, Ophélie Gourbeyre1,2, Christophe Chambon3,
Lydie Combaret1,2, Cécile Polge1,2, Daniel Taillandier1,2, Didier Attaix1,2, Bertrand Friguet4, Andrea B Maier5,
Gillian Butler-Browne6 and Daniel Béchet1,2*Abstract
Background: Muscle ageing contributes to both loss of functional autonomy and increased morbidity. Muscle
atrophy accelerates after 50 years of age, but the mechanisms involved are complex and likely result from the
alteration of a variety of interrelated functions. In order to better understand the molecular mechanisms underlying
muscle chronological ageing in human, we have undertaken a top-down differential proteomic approach to identify
novel biomarkers after the fifth decade of age.
Results: Muscle samples were compared between adult (56 years) and old (78 years) post-menopausal women.
In addition to total muscle extracts, low-ionic strength extracts were investigated to remove high abundance
myofibrillar proteins and improve the detection of low abundance proteins. Two-dimensional gel electrophoreses
with overlapping IPGs were used to improve the separation of muscle proteins. Overall, 1919 protein spots were
matched between all individuals, 95 were differentially expressed and identified by mass spectrometry, and they
corresponded to 67 different proteins. Our results suggested important modifications in cytosolic, mitochondrial
and lipid energy metabolism, which may relate to dysfunctions in old muscle force generation. A fraction of the
differentially expressed proteins were linked to the sarcomere and cytoskeleton (myosin light-chains, troponin T,
ankyrin repeat domain-containing protein-2, vinculin, four and a half LIM domain protein-3), which may account for
alterations in contractile properties. In line with muscle contraction, we also identified proteins related to calcium
signal transduction (calsequestrin-1, sarcalumenin, myozenin-1, annexins). Muscle ageing was further characterized
by the differential regulation of several proteins implicated in cytoprotection (catalase, peroxiredoxins), ion
homeostasis (carbonic anhydrases, selenium-binding protein 1) and detoxification (aldo-keto reductases, aldehyde
dehydrogenases). Notably, many of the differentially expressed proteins were central for proteostasis, including heat
shock proteins and proteins involved in proteolysis (valosin-containing protein, proteasome subunit beta type-4,
mitochondrial elongation factor-Tu).
Conclusions: This study describes the most extensive proteomic analysis of muscle ageing in humans, and
identified 34 new potential biomarkers. None of them were previously recognized as differentially expressed in
old muscles, and each may represent a novel starting point to elucidate the mechanisms of muscle chronological
ageing in humans.
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Ageing affects most tissues and physiologic functions,
and one of the most affected organs is the skeletal
muscle. The progressive decline in muscle mass and
function due to ageing, which is also referred to as sar-
copenia [1], contributes to both loss of autonomy [2],
increased prevalence of falls, decreased resistance to
metabolic aggression that increases morbidity [3] and
mortality [4]. Numerous theories have been proposed to
explain muscle ageing. Obviously, this is a multifactorial
phenomenon which implicates intrinsic factors such as
perturbations in the endocrine system, neuronal remo-
delling, oxidative stress and deficiencies in muscle rege-
neration, extrinsic factors such as diet and exercise, and
also probably other unknown mechanisms [5].
Age-related degenerative changes are reflected in alter-
ations in muscle morphology, function, and biochemical
properties. Muscle ageing is thus associated with muscle
fiber atrophy [6,7], reduced muscle regenerative capacity
[8], and neuropathic processes leading to motor unit
denervation [9]. Mitochondrial dysfunctions with de-
creased capacity of oxidative enzymes and a decline of
mitochondrial ATP production may also be observed
with ageing in skeletal muscles [10-12].
The overall functional, structural, and biochemical al-
terations in ageing muscle have been extensively studied,
but the molecular mechanisms implicated remain to be
specified. The differential expression profiles of mRNAs
constitute a first essential level of information, but ana-
lyses of the expression profile of proteins in ageing are
also required to understand the molecular mechanisms
important for the muscle ageing process [13]. In fact,
unlike the genome, the proteome varies in response to
many physiological or pathological factors. In addition,
the proteome is orders of magnitude more complex than
the transcriptome due to post-translational modifications,
protein oxidation or limited protein degradation [14].
Several studies have been conducted in rat muscle and
proteomic profiling has demonstrated substantial alter-
ations in muscle proteins involved in key metabolic path-
ways, myofibrillar remodelling, cytoskeleton organisation
and mechanisms of cytoprotection and cytodetoxification
[15-19]. However, few studies have been conducted with
human muscle and results are contradictory. Gelfi et al.
[20] have shown that several enzymes involved in oxidative
metabolism, including ubiquinol-cytochrome c reductase
or aspartate aminotransferase, were more abundant in
elderly than in young people, while Short et al. [11] have
demonstrated a decrease in these enzymes with ageing. In
contrast, some results observed in rat muscle proteomic
analyses were confirmed in human muscle, such as a
decrease in enzymes involved in glycolytic metabolism and
an increase in proteins involved in cytoprotection (car-
bonic anhydrase 3) and cytodetoxification (Hsp70) [20,21].Because epidemiological studies have indicated acce-
lerated muscle wasting after the fifth decade with an ap-
proximately 2% reduction in muscle mass per year [22],
we have undertaken a top-down differential proteomic
approach to determine potential changes after the fifth
decade of life and to identify novel biomarkers of muscle
ageing. In a previous study, we used a shot-gun proteo-
mics approach to identify 35 potential biomarkers [23].
Herein, we performed two dimensional gel electro-
phoreses (2DGE) using biopsies of vastus lateralis from
mature adult (56 years) vs. old (78 years) women, and
for better separation of proteins, two different strategies
were conducted. Firstly, overlapping immobilized pH
gradient (IPG) with three different pH ranges were used
to improve muscle proteins separation, and secondly, we
assessed low salt extracts to remove the high abundance
myofibrillar proteins and improve the detection of low
abundance proteins. The proteomic profiling of aged
skeletal muscle fibers revealed a differential expression
pattern of 67 potential biomarkers important for energy
metabolism, contractile properties, calcium signaling,
cytoprotection, regulation of protein misfolding, and
proteolysis. The present study demonstrates that alter-
ations of muscle function in elderly women are associa-
ted with severe perturbed protein expression patterns
and identified 34 new potential biomarkers of sarcopenia
that had not previously been described.
Results and discussion
Differentially expressed proteins during ageing
In order to evaluate age-dependent alterations in the ske-
letal muscle proteome after the fifth decade of life, total
muscle extracts from biopsies of mature adult (56 years)
versus old (78 years) post-menopausal women were re-
solved by 2DGE. Gels with overlapping range of IPGs
were used to improve the separation of total muscle ex-
tracts. 2DGE with medium range IPGs (pH 5–8) revealed
839 protein spots that were matched between all indivi-
duals. Among these protein spots, 56 were found to be
differentially expressed between adult and old women,
and 31 were identified by liquid chromatography coupled
to tandem mass spectrometry (LC-MS/MS), correspon-
ding to 27 different proteins (Figure 1A). 2DGE with
acidic IPGs (pH 3.0-5.6) distinguished 202 matched pro-
tein spots, and among them 8 were differentially expressed
and identified as 6 different proteins (Figure 1B). Narrow
IPGs were also used to achieve optimal resolution in the
pH 5.3-6.5 range, and this revealed a further 179 matched
spots. Among these 179 spots, statistical analysis revealed
3 differentially expressed spots which were identified by
LC-MS/MS as 3 different proteins (Figure 1C).
Because myofibrillar proteins may hamper the detec-
tion of low abundance proteins, we also precipitated
myofibrils at low ionic strength [24,25], and focused on
Figure 1 Representative 2DGE image obtained from total protein extracts of human vastus lateralis skeletal muscle. 2DGE was
performed using a pH range of 5–8 (A), 3–5.6 (B) or 5.6-6.5 (C) in first dimension and SDS-PAGE (11%T) in the second. Protein loading was 700
μg, and the gels were stained using colloidal Coomassie blue G-250. Differentially expressed and identified proteins are marked and spot numbers
refer to Table 1.
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gels with medium range IPGs (pH 5–8) were used to
analyze LIS extracts and 699 protein spots were matched
between all individuals. Statistical analysis revealed that86 spots were differentially expressed between adult and
old women. Among them, 55 were identified by LC-MS/MS
(Figure 2), and they corresponded to 37 different proteins.
Targeting the LIS sub-proteome improved the 2DGE
Figure 2 Representative 2DGE image obtained from low ionic strength (LIS) extracts of human vastus lateralis skeletal muscle. 2DGE
was performed using a pH range of 5–8 in the first dimension and SDS-PAGE (11%T) in the second. Protein loading was 700 μg, and the gels
were stained using colloidal Coomassie blue G-250. Differentially expressed and identified proteins are marked and spot numbers refer to Table 2.
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differentially expressed LIS proteins were not found in
total muscle extracts.
Interestingly, shot-gun proteomics previously identified
35 potential biomarkers in the LIS sub-proteome [23]. It
should be noted that, although shot-gun and 2DGE prote-
omics are based on different strategies (analyses of tryptic
digests and intact protein isoforms, respectively), the two
techniques are complementary, as only 6 common proteins
were found in both investigations: titin (TTN), ankyrin re-
peat domain-containing protein 2 (ANKRD2), L-lactate
dehydrogenase β (LDHB), furamate hydratase (FH), fatty
acid binding protein 4 (FABP4) and carbonic anhydrase 3
(CA3). Overall in the present 2DGE study, 1919 protein
spots were matched between all individuals, 95 were
differentially expressed and identified, and they corre-
sponded to 67 different proteins. Table 1 (for total muscle
extract) and Table 2 (for LIS extract) summarize the main
properties of the proteins differentially regulated in ske-
letal muscle between adult and old post-menopausalwomen. Absolute fold changes varied from 1.1 to 2.6.
Even though some fold-changes appeared relatively small,
there were parallel changes of several components in each
pathway or biological process, suggesting some important
coordinated and specific regulations.
Perturbations of the myofilament network and
cytoskeleton with ageing
Sarcomeric proteins
Muscle contraction is generated by an interaction between
the molecular motor myosin and filamentous actin.
Myosin is a hexameric protein that consists of two heavy
chain subunits, two alkali light chain subunits and two
regulatory light chain subunits. Myosin light chains typic-
ally exhibit various isoforms, and in our study, muscle
ageing was associated with higher level of one myosin
light chain 1/3 skeletal muscle isoform (MYL1, spot 1882)
and lower level of one myosin regulatory light chain 2
ventricular/cardiac muscle isoform (MYL2, spot 2032).
Perturbations in myofibrillar contractile proteins were
Table 1 Differentially expressed muscle proteins in total extract between adult (56 yr) and old (78 yr) post-menauposal women
2DGE
pH
Spot
n°
Accession Symbol Protein name Fold
change
Age effect (p
value)
Mascot
score
Sequence
coverage (%)
Unique
peptides
Main biological function
5-8 1882 P05976 MYL1 Myosin light chain 1/3 +1.4 0.020 693 41 5 Myofilaments and cytoskeleton
5-8 2032 P10916 MYL2 Myosin regulatory light chain 2 −1.7 0.012 4807 86 15 Myofilaments and cytoskeleton
5-8 1123 P45378 TNNT3 Troponin T, fast skeletal muscle +1.9 0.033 288 24 4 Myofilaments and cytoskeleton
5-8 1333 P68133 ACTA1 Actin, alpha skeletal muscle (N-term fragment) +1.7 0.042 999 23 4 Myofilaments and cytoskeleton
5-8 1415 P68133 ACTA1 Actin, alpha skeletal muscle (N-term fragment) +1.3 0.034 847 29 4 Myofilaments and cytoskeleton
5-8 1417 P68133 ACTA1 Actin, alpha skeletal muscle (C-term fragment) +1.3 0.041 350 19 4 Myofilaments and cytoskeleton
5-8 570 P12882 MYH1 Myosin-1 (C-term fragment) +2.3 0.011 712 9 11 Myofilaments and cytoskeleton
3-5.6 665 P31415 CASQ1 Calsequestrin-1 +1.4 0.045 1146 22 9 Signal transduction
5-8 858 Q86TD4 SRL Sarcalumenin (mature C-term) −1.6 0.008 1606 44 17 Signal transduction
5-8 3260 Q9NP98 MYOZ1 Myozenin-1 +1.7 0.008 435 22 4 Signal transduction
3-5.6 758 P20073 ANXA7 Annexin A7 +1.8 0.029 954 15 6 Signal transduction, autophagy
5-8 300 P06732 CKM Creatine kinase M-type (dimer) −1.7 0.031 445 25 7 Energy metabolism
5-8 332 P06732 CKM Creatine kinase M-type (dimer) −1.7 0.048 737 39 11 Energy metabolism
5-8 391 P11217 PYGM Glycogen phosphorylase, muscle form −2.6 0.031 1516 39 23 Energy metabolism,
glycogenolysis
5.3-6.5 1874 P21695 GPD1 Glycerol-3-phosphate dehydrogenase [NAD+],
cytoplasmic
−1.4 0.040 3383 53 17 Energy metabolism, shuttle
5-8 3459 Q8N335 GPD1L Glycerol-3-phosphate dehydrogenase 1-like
protein
−1.4 0.022 1884 55 14 Energy metabolism, shuttle,
hypoxia
5-8 3511 P60174 TPI1 Triosephosphate isomerase +1.3 0.050 798 56 9 Energy metabolism, glycolysis,
detoxification
5-8 1196 P11177 PDHB Pyruvate dehydrogenase E1 component subunit
beta
−1.3 0.043 2267 59 14 Energy metabolism, Krebs cycle
5-8 769 P09622 DLD Dihydrolipoyl dehydrogenase, mitochondrial −1.4 0.010 466 29 8 Energy metabolism, Krebs cycle
5-8 577 Q99798 ACO2 Aconitate hydratase, mitochondrial −1.6 0.043 365 19 9 Energy metabolism, Krebs cycle
5-8 984 O75306 NDUFS2 NADH dehydrogenase [ubiquinone] iron-sulfur
protein 2, mitochondrial
−1.6 0.005 1777 49 15 Energy metabolism, oxidative
phosphorylation
5-8 3417 P47985 UQCRFS1 Cytochrome b-c1 complex subunit Rieske,
mitochondrial
−1.3 0.031 1271 23 5 Energy metabolism, oxidative
phosphorylation
3-5.6 2713 P20674 COX5A Cytochrome c oxidase subunit 5A, mitochondrial −1.5 0.015 779 48 6 Energy metabolism, oxidative
phosphorylation
5-8 909 P06576 ATP5B ATP synthase subunit beta −1.4 0.023 2725 62 20 Energy metabolism, oxidative
phosphorylation
5-8 2371 P05413 FABP3 Fatty acid-binding protein, heart −1.4 0.004 2281 77 11 Energy metabolism, lipid
transport
5-8 3328 P15121 AKR1B1 Aldose reductase −1.5 0.016 323 31 5 Detoxification, cytoprotection
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Table 1 Differentially expressed muscle proteins in total extract between adult (56 yr) and old (78 yr) post-menauposal women (Continued)
3-5.6 1414 P04792 HSPB1 Heat shock protein beta-1 +1.7 0.019 714 36 5 Detoxification, cytoprotection
5.3-6.5 2375 P04792 HSPB1 Heat shock protein beta-1 +1.3 0.026 484 41 6 Detoxification, cytoprotection
5-8 678 P08107 HSPA1A Heat shock 70 kDa protein 1A/1B +1.1 0.014 3630 52 14 Detoxification, cytoprotection
5-8 3332 P38646 HSPA9 Stress-70 protein, mitochondrial +1.4 0.008 5401 45 22 Detoxification, cytoprotection
5-8 3289 P00918 CA2 Carbonic anhydrase 2 +1.3 0.047 1605 54 11 Detoxification, cytoprotection
5-8 877 Q13228 SELENBP1 Selenium-binding protein 1 −1.5 0.028 1677 56 19 Detoxification, cytoprotection
5.3-6.5 2410 P28070 PSMB4 Proteasome subunit beta type-4 −1.4 0.049 1692 33 5 Proteolysis
3-5.6 3387 P54725 RAD23A UV excision repair protein RAD23 homolog A −1.3 0.041 309 28 6 Proteolysis
5-8 3270 P49411 TUFM Elongation factor Tu, mitochondrial −1.4 0.001 1548 38 12 Protein synthesis, proteolysis
5-8 919 P02679 FGG Fibrinogen gamma chain −1.3 0.026 1023 59 16 Serum
5-8 1429 P30042 C21orf33 ES1 protein homolog, mitochondrial −1.6 0.001 364 51 6 Miscellaneous
5-8 1430 P30042 C21orf33 ES1 protein homolog, mitochondrial −1.7 0.002 118 18 3 Miscellaneous
5-8 1177 Q9H0P0 NT5C3 Cytosolic 5'-nucleotidase 3 −1.6 0.015 589 35 10 Miscellaneous
3-5.6 1429 Q9Y235 APOBEC2 Apolipoprotein B mRNA-editing enzyme, catalytic
polypeptide-like 2
−1.2 0.018 1904 74 11 Miscellaneous
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Table 2 Differentially expressed muscle proteins in low ionic strength (LIS) extract between adult (56 yr) and old (78 yr) post-menauposal women
Spot
n°
Accession Symbol Protein name Fold
change
Age effect (p
value)
Mascot
score
Sequence
coverage (%)
Unique
peptides
Main biological function
1734 E7ENC6 TTN Titin (C-term fragment) −1.4 0.032 4511 1 11 Myofilaments and cytoskeleton
1361 Q9GZV1 ANKRD2 Ankyrin repeat domain-containing protein 2 +1.8 0.033 1831 51 14 Myofilaments and cytoskeleton
522 P18206-2 VCL Vinculin, isoform 1 +1.5 0.048 1457 21 17 Myofilaments and cytoskeleton
526 P18206-2 VCL Vinculin, isoform 1 +1.6 0.026 1329 26 20 Myofilaments and cytoskeleton
1418 Q13643 FHL3 Four and a half LIM domains protein 3 −1.5 0.038 1046 42 8 Myofilaments and cytoskeleton
1179 P10644 PRKAR1A cAMP-dependent protein kinase type I-alpha
regulatory subunit
+1.6 0.021 903 37 11 Signal transduction
1494 P04083 ANXA1 Annexin A1 +1.3 0.049 4205 59 17 Signal transduction, dystrophies
1619 P08758 ANXA5 Annexin A5 +1.5 0.005 3264 64 16 Signal transduction, membrane
repair
1673 P78417 GSTO1 Glutathione S-transferase omega-1 −1.5 0.049 674 44 7 Detoxification, signal transduction
1261 P06732 CKM Creatine kinase M-type −1.3 0.019 3974 45 15 Energy metabolism
1266 P06732 CKM Creatine kinase M-type −1.2 0.044 6576 50 16 Energy metabolism
1276 P06732 CKM Creatine kinase M-type −1.2 0.017 8749 57 17 Energy metabolism
1289 P06732 CKM Creatine kinase M-type −1.1 0.044 10394 52 17 Energy metabolism
3617 P06732 CKM Creatine kinase M-type −1.4 0.037 3259 43 13 Energy metabolism
516 P06732 CKM Creatine kinase M-type (trimer) −1.2 0.022 5360 54 16 Energy metabolism
289 P11217 PYGM Glycogen phosphorylase, muscle form +1.4 0.019 3091 48 28 Energy metabolism, glycogenolysis
659 F5GZH7 PYGM Phosphorylase +1.3 0.027 4260 49 31 Energy metabolism, glycogenolysis
676 F5GZH7 PYGM Phosphorylase +1.7 0.004 662 24 12 Energy metabolism, glycogenolysis
696 F5GZH7 PYGM Phosphorylase +1.5 0.004 917 23 15 Energy metabolism, glycogenolysis
998 P36871 PGM1 Phosphoglucomutase-1 −1.3 0.017 1772 33 14 Energy metabolism, glycogenolysis
1209 P13929 ENO3 Beta-enolase −1.3 0.005 3382 41 12 Energy metabolism, glycolysis
1210 P13929 ENO1/3 Alpha/beta-enolase −1.7 0.027 5218 53 12 Energy metabolism, glycolysis
1213 P13929 ENO3 Beta-enolase −1.3 0.044 9731 62 20 Energy metabolism, glycolysis
1215 P13929 ENO3 Beta-enolase −1.6 0.014 3548 49 13 Energy metabolism, glycolysis
1236 P13929 ENO3 Beta-enolase −1.2 0.011 12846 62 22 Energy metabolism, glycolysis
1448 P07195 LDHB L-lactate dehydrogenase B chain −1.3 0.043 2156 46 11 Energy metabolism, glycolysis
1229 P07954-2 FH Fumarate hydratase −1.4 0.010 2328 44 12 Energy metabolism, Krebs cycle
3215 P15090 FABP4 Fatty acid-binding protein, adipocyte +1.5 0.038 4748 70 10 Energy metabolism, lipid, ER stress
1007 P04040 CAT Catalase −1.3 0.026 654 21 9 Detoxification, cytoprotection
1754 E9PH29 PRDX3 Thioredoxin-dependent peroxide reductase,
mitochondrial
+1.5 0.012 1802 47 9 Detoxification, cytoprotection
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Table 2 Differentially expressed muscle proteins in low ionic strength (LIS) extract between adult (56 yr) and old (78 yr) post-menauposal women (Continued)
1858 Q99497 PARK7 Protein DJ-1 +1.2 0.043 334 42 6 Detoxification, cytoprotection
1107 P05091 ALDH2 Aldehyde dehydrogenase +1.2 0.012 7985 48 19 Detoxification, cytoprotection
1351 P14550 AKR1A1 Alcohol dehydrogenase +1.4 0.006 1387 46 13 Detoxification, cytoprotection
1011 P30038 ALDH4A1 Delta-1-pyrroline-5-carboxylate dehydrogenase −1.2 0.027 1219 21 9 Amino acid metabolism
1762 P04792 HSPB1 Heat shock protein beta-1 +1.3 0.027 1453 51 7 Detoxification, cytoprotection
1763 P04792 HSPB1 Heat shock protein beta-1 +1.3 0.029 1286 51 8 Detoxification, cytoprotection
2356 E9PR44 HSPB5 Alpha-crystallin B chain +1.5 0.038 1046 39 6 Detoxification, cytoprotection
2364 O14558 HSPB6 Heat shock protein beta-6 +1.2 0.043 597 71 4 Detoxification, cytoprotection
755 P08238 HSPC2/3 Heat shock protein HSP 90-alpha/beta +1.9 0.035 3256 38 12 Detoxification, cytoprotection
1081 B3KQT9 PDIA3 Protein disulfide-isomerase A3 +1.4 0.012 965 36 15 Detoxification, cytoprotection
812 P00918 CA2 Carbonic anhydrase 2 +1.2 0.038 3352 72 15 Detoxification, cytoprotection
1752 P07451 CA3 Carbonic anhydrase 3 +1.2 0.004 3663 58 11 Detoxification, cytoprotection
1755 P07451 CA3 Carbonic anhydrase 3 +1.2 0.025 6098 72 14 Detoxification, cytoprotection
1119 Q13228 SELENBP1 Selenium-binding protein 1 +1.2 0.006 4100 70 23 Detoxification, cytoprotection
1127 Q13228 SELENBP1 Selenium-binding protein 1 +1.2 0.036 3543 63 21 Detoxification, cytoprotection
3614 P22314 UBA1 Ubiquitin-like modifier-activating enzyme 1 +1.8 0.033 7675 42 29 Proteolysis
3654 P55072 VCP Transitional endoplasmic reticulum ATPase +1.5 0.011 1920 39 23 Proteolysis
1088 P12955 PEPD Xaa-Pro dipeptidase +1.4 0.021 948 24 9 Proteolysis
1014 P01008 SERPINC1 Antithrombin-III −1.2 0.014 3612 44 18 Proteolysis
1070 P02774 GC Vitamin D-binding protein −1.4 0.008 2704 40 14 Serum
2892 P02766 TTR Transthyretin −1.3 0.026 3695 65 8 Serum
1847 P02647 APOA1 Apolipoprotein A-I −1.5 0.002 5385 55 15 Serum
1855 P02647 APOA1 Apolipoprotein A-I −1.5 0.004 8189 54 15 Serum
3624 P02647 APOA1 Apolipoprotein A-I −1.3 0.042 1347 41 8 Serum
681 P02787 TF Serotransferrin +1.7 0.047 1523 38 16 Serum
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troponin T (TNNT3, spot 1123) which is a major regula-
tor of the thin filament. Troponin T directly interacts with
key components in the thin filament regulatory system to
mediate the activation and force development of acto-
myosin contractile units [26]. Age-related changes in
fibers expressing various myosin light chain isoforms
were previously described for MYL1, MYL2 and TNNT3
[15,17,20]; however, these changes were manifested diffe-
rentially in distinct muscles.
Interestingly, the old skeletal muscle also exhibited al-
tered levels of several fragments of sarcomeric proteins.
Thus, there were higher levels of N-terminal (spots 1333
and 1415) and C-terminal (spot 1417) fragments of skeletal
α-actin (ACTA1), and a higher level of a C-terminal frag-
ment (spot 570) of myosin-1 (MYH1), the type IIX adult
fast myosin heavy chain. The old muscle also exhibited
lower level of a C-terminal fragment of TTN (LIS-spot
1734), when compared to adult muscle. Such fragments
were not observed for non-sarcomeric proteins, and may
indicate perturbations in sarcomeric proteolytic pathways.
A feature of human muscle ageing was also the in-
creased expression of ankyrin repeat domain-containing
protein 2 (ANKRD2, LIS-spot 1361). ANKRD2 is a
member of the mechano-sensing proteins that link myofi-
brillar stress response to muscle gene expression [27,28].
ANKRD2 interacts both with I-band sarcomeric proteins
and with nuclear transcription factors [29]. This stretch-
response protein is preferentially expressed in slow type-I
fibers, and is induced by denervation, which is consistent
with neuronal remodeling in ageing muscle [30].
Aging of skeletal muscle involves a decrease in both
total number (hypoplasia) and size (atrophy) of muscle
fibers. No consensus has been reached in the literature on
whether hypoplasia is associated with a shift in fiber type
distribution towards higher [31-33], lower [34,35] or
unaltered [12,36,37] percentages of type-I versus type-II
fibers. However, previous studies based on myosin heavy
chain (MYH) histochemistry agreed that atrophy mostly
affects type-II fibers [12,31,32,34,38]. In our 2DGE ana-
lyses, there was no clear evidence for a fast-to-slow transi-
tion on the unique basis of the differential expression of
myosin light chain and troponin isoforms.
Cytoskeletal proteins
The integrity of muscle fibers depends on cytoskeletal
components, which align sarcomeres and anchor them
across the sarcolemma to the basement membrane [39].
Two isoforms of vinculin (VCL, LIS-spots 522 and 526)
were enhanced during ageing. VCL localizes to adhesion
junctions and is a central component of muscle costa-
meres [40,41]. VCL is placed between the integrin-talin
complex and the actin cytoskeleton and is a major can-
didate for transduction of force during the contractilecycle. Besides binding to actin, VCL interacts with signa-
ling networks and is important for signal transduction bet-
ween the extracellular matrix and the cytoskeleton [42].
Finally, the four and a half LIM domain protein 3
(FHL3, LIS-spot 1418), which is down-regulated in our
analysis, is an adaptor protein with numerous interaction
partners. In adult fibers, FHL3 interacts with cytoskeletal
actin [43] and co-localizes with integrin receptors at the
periphery of Z-discs [44]. By binding to integrin and
actin, FHL3 might then directly link the cytoskeleton to
the extracellular matrix. FHL3 also plays a role in myo-
genic progenitor cells (satellite cells), where it localizes
to the nucleus and has been implicated in the regulation
of proliferation [45] and differentiation [46].
VCL and FHL3 have not been previously identified
by proteomic surveys of human skeletal muscle ageing
[11,20,21]. Shot-gun proteomics confirmed the up-regula-
tion of ANKRD2 [23], and Western blotting experiments
performed with total muscle extracts confirmed the diffe-
rential expressions that we observed for VCL and FHL3 in
LIS extracts (Figure 3A and B). In all, the modifications
that we report for sarcomeric actomyosin and cytoskeletal
proteins are most likely related to disorganization of myo-
fibers in old muscles. Moreover, these changes suggest an
influence of the ageing process on the maintenance of the
proper organization of sarcolemma in regular structures
that are closely linked to costameres, and on the response
to extracellular signals. Thus, the age-related changes in
sarcomeric and cytoskeletal proteins may result in alter-
ations in contractile properties and contribute to the de-
velopment of sarcopenia.
Age-related changes in skeletal muscle affect signal
transduction
In skeletal muscle, intracellular calcium (Ca2+) is an
important secondary messenger for signal transduction
and is essential for cellular processes such as excitation-
contraction coupling. Action potentials elicit contractions
by releasing Ca2+ from the sarcoplasmic reticulum (SR)
via the ryanodine receptors (RyRs). RyRs are modulated
directly or indirectly by various ions, small molecules and
proteins, including calsequestrin. In this study, proteomics
analysis of muscle ageing identified an up-regulation of
calsequestrin-1 (CASQ1, spot 665), which is a major intra-
SR Ca2+ buffer that regulates the activity of RyRs [47,48].
RyR receptors have several potential phosphorylation
sites in their cytoplasmic domains and protein kinase A
(PKA) has been shown to phosphorylate RyRs. Our
analysis shows an increased level of the PKA type Iα
regulatory subunit (PRKAR1A, LIS-spot 1179) during
ageing. Among other substrates PKA can phosphorylate
RyR, and PKA-mediated phosphorylation of RyR may
result in leaky RyR channels and impaired Ca2+ homeo-
stasis [49,50].
Figure 3 Examples of differential expression of cytoskeletal proteins. Representative sections of 2DGE images (left panel) and representative
Western blots (right panel) for vinculin (VCL) (A) and four and a half LIM domains 3 (FHL3) (B). In each panel, histograms represent normalized
volume of protein spot (n = 6), and Western blot quantification (n = 7) for adult and old post-menopausal women. Results are indicated as
means ± SE. *: P <0.05 indicates significant difference between adult and old women.
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cytoplasmic Ca2+, Ca2+ is pumped back to the SR by
sarcoplasmic reticulum Ca2+ ATPase (SERCA) leading
to relaxation. Sarcalumenins (SRL) are major luminal
glycoproteins that codistribute with SERCA and play a
role in Ca2+ transport and sequestration [51,52]. There
are two SRL isoforms (160-kDa and 53-kDa) that are
generated by alternative splicing [51]. In the present
study, the 53-kDa isoform (spot 858) was found to be re-
duced in aged human muscle, and this reduction was
confirmed by Western-blotting (Figure 4A). The age-
related decrease of SRL is in agreement with previous
studies in rat muscle indicating a shorter half-life of the
53-kDa isoform [53] and a lower level of the 160-kDa
isoform [54].
We have also identified an up-regulation of myozenin-1
(MYOZ1, also termed calsarcin-2, spot 3260) which is
expressed in fast-twitch fibers of skeletal muscle and mo-
dulates the function and substrate specificity of cal-
cineurin, a Ca2+/calmodulin-dependent serine-threonine
phosphatase that plays an important role in transducing
calcium-dependent signals [55]. This increase in MYOZ1
was also confirmed by Western-blotting (Figure 4B).
In skeletal muscle, numerous proteins can bind Ca2+,
and muscle ageing was further associated with higher level
of three members of the annexin family which undergo
Ca2+-dependent binding to the cellular membranes. Weidentified annexin A1 (ANXA1 or lipocortin I, LIS-spot
1494), A5 (ANXA5, LIS-spot 1619) and A7 (ANXA7 or
Synexin, spot 758). Annexins have been involved in a
broad range of molecular and cellular processes. Note-
worthy ANXA1 may contribute to the regeneration of
skeletal muscle tissue by modulating migration [56] and
fusion [57] of satellite cells. ANXA1 is overexpressed in
different muscular dystrophies [58] and can further par-
ticipate in sarcolemmal and T-tubular repair processes
[59]. ANXA5 also promotes membrane repair by self-
assembling into two-dimensional arrays on membranes
[60]. ANXA7 was originally described as a protein that
provokes fusion of lipid vesicules [61]. More recently,
ANXA7 was identified as an essential protein for auto-
phagy induction by modulating the intracellular Ca2+ con-
centration [62]. Western-blotting experiments confirmed
the overexpression of ANXA1 and ANXA5 (Figure 4C
and D) in total extracts of old muscle, compared to adult
muscle.
Glutathione S-transferase omega-1 (GSTO1) is distin-
guished from the other glutathione S-transferase family
members by a different active center amino acid residue,
which results in loss of prototypical glutathione conju-
gating activity [63]. Instead, human GSTO1 is reported to
potentiate skeletal muscle ryanodine receptor (RyR1) [64].
The age-related down-regulation of GSTO1 (LIS-spot
1673) was confirmed by Western-Blot (Figure 4E), and
Figure 4 Examples of differential expression of proteins implicated in signal transduction. Representative sections of 2DGE images (left
panel) and representative Western blots (right panel) for sarcalumenin (SRL) (A), myozenin-1 (MYOZ1) (B), annexin A1 (ANXA1) (C), annexin A5
(ANXA5) (D) and glutathione S-transferase omega-1 (GSTO1) (E). In each panel, histograms represent normalized volume of protein spot (n = 5–6),
and Western blot quantification (n = 7) for adult and old post-menopausal women. Results are indicated as means ± SE. *: P <0.05 indicates
significant difference between adult and old women.
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homeostasis.
Most of these signal transduction proteins (CASQ1,
PRKAR1A, MYOZ1, ANXA1 and ANXA7) have never
been reported in previous proteomic studies of muscle
ageing. Overall, our findings suggest significant alter-
ations in Ca2+ signaling which may be important for the
age-related modifications in muscle contractile proper-
ties and may contribute to muscle weakness.
Perturbations in the energy metabolism of old muscle
Disturbance in energy metabolism is another character-
istic feature of old muscles. Decreased activities of gly-
colytic enzymes were previously reported in rat [15] and
in human [20] skeletal muscles, whereas expression of
mitochondrial enzymes was more controversial in the
literature [11,20]. Our study points to an age-associated
decline in key enzymes of the glycolytic, Krebs cycle and
oxidative phosphorylation pathways.
Cytoplasmic energy metabolism
In the current study, perturbations in the energy metabo-
lism of old muscle were indicated by the down-regulation
of five isoforms of monomeric creatine kinase (CKM)
(LIS-spots 1261, 1266, 1276, 1289 and 3617). SDS-stable
dimeric and trimeric forms of CKM were previously
described in mice muscle [65], and we also observed age-
related decreases in dimeric (spots 300 and 332) and
trimeric (LIS-spot 516) forms of CKM. Creatine/phospho-
creatine is central to maintain energetic homeostasis as it
connects intracellular sites of energy demand with sites of
ATP production. At these sites, CKM catalyses the trans-
phosphorylation between phosphocreatine and ADP. In
sarcomeric M-line, CKM interacts with myomesin and
supplies ATP for the actomyosin contractile unit.
The first step of glycogenolysis pathway is the produc-
tion of glucose-6-phosphate by glycogen phosphorylase
(PYGM), which catalyzes the phosphorolytic cleavage of
a glucosyl residue from the glycogen polymer. Four
isoforms (LIS-spots 289, 659, 676 and 696) of PYGM
increased, and one (spot 391) decreased with ageing.
The resulting glucose 1-phosphate molecule is con-
verted by phosphoglucomutase to glucose 6-phosphate.
Proteomic analysis revealed a decreased expression of
phosphoglucomutase-1 (PGM1, LIS-spot 998) in elderly
women. Several glycolytic enzymes were also down-
regulated with ageing. Enolase catalyzes the conversion
of 2-phosphoglycerate to phosphoenolpyruvate. In the
muscle of post-menopausal women, four isoforms of the
muscle specific β-enolase (ENO3, LIS-spots 1209, 1213,
1215 and 1236) were selectively decreased during ageing.
We also detected lower levels of LDHB (LIS-spot 1448)
which catalyzes the inter-conversion of pyruvate (the final
product of glycolysis) and lactate with concomitant inter-conversion of NADH and NAD+. Finally, down-regulations
of glycerol-3-phosphate dehydrogenase (GPD1, spot 1874)
and glycerol-3-phosphate dehydrogenase 1-like protein
(GPD1L, spot 3459) were observed. Cytosolic GPD1, to-
gether with its mitochondrial isoform, constitute the GPD1
shuttle, which is essential for mitochondrial oxidation of
glycolytic NADH. Although less active than its GPD1
counterpart, GPD1L exhibits dehydrogenase activity, and is
also implicated in the regulation of hypoxia [66]. Age-
related decline in cytoplasmic glycerol-3-phosphate de-
hydrogenase may indicate reduced mitochondrial oxidation
of cytosolic NADH in old muscle.
Triosephosphate isomerase (TPI1, spot 3511), that cata-
lyzes the isomerization of the dihydroxyacetone phosphate
(DHAP) and D-glyceraldehyde 3-phosphate, was the only
glycolytic enzyme more abundant in old muscle. TPI1 en-
sures that DHAP produced by aldolase is further metabo-
lized by the glycolytic enzymes. Impairment of TPI1 can
result in chemical conversion of DHAP into toxic methyl-
glyoxal [67] promoting the formation of advanced glyca-
tion end-products. In the old muscle, an increased level of
TPI1 may then represent a compensatory adaptation to
avoid excessive formation of toxic products [68].
Mitochondrial energy metabolism
Alterations in the mitochondrial Krebs cycle were re-
vealed by the age-dependent reduction in two subunits
of the pyruvate dehydrogenase, pyruvate dehydrogenase
E1 component subunit β (PDHB, spot 1196) and dihy-
drolipoyl dehydrogenase (DLD, spot 769), and by the re-
duction in aconitate hydratase (ACO2, spot 577) and FH
(LIS-spot 1229), two enzymes that catalyze the isome-
rization of citrate to isocitrate and the hydration of fura-
mate to malate, respectively. Moreover, alterations in
oxidative phosphorylation were also revealed by lower
levels of three components of the respiratory chain,
NADH dehydrogenase iron-sulfur protein 2 of complex
I (NDUFS2, spot 984), cytochrome b-c1 complex sub-
unit Rieske of complex III (UQCRFS1, spot 3417) and
subunit 5A of cytochrome c oxidase of complex IV
(COX5A, spot 2713). Ageing was further associated with
lower level of ATP synthase subunit β (ATP5B, spot
909). Among these proteins implicated in energy meta-
bolism, two (NDUFS2 and UQCRFS1) have never been
reported in previous muscle ageing studies, and FH and
ATP5B were similarly found in our shot-gun experiment
[23]. Western blotting experiments confirmed alterations
in glycolytic and oxidative metabolism, as we observed
decreased expression of ENO3, GPD1, NDUFS2 and
UQCRFS1, in total extracts of old muscle compared to
adult muscle (Figure 5). Concomitant decreases of key
enzymes of Krebs cycle and major complexes of oxida-
tive phosphorylation provided evidences for alteration of
mitochondrial metabolism in the old skeletal muscle.
Figure 5 Examples of differential expression of proteins implicated in energy metabolism. Representative sections of 2DGE images (left
panel) and representative Western blots (right panel) for β-enolase (ENO3) (A), glycerol-3-phosphate dehydrogenase [NAD+] (GPD1) (B), NADH
dehydrogenase (ubiquinone) Fe-S protein 2 (NDUFS2) (C) and cytochrome b-c1 complex subunit Rieske (UQCRFS1) (D). In each panel, histograms
represent normalized volume of protein spot (n = 5–6), and Western blot quantification (n = 7) for adult and old post-menopausal women. Results
are indicated as means ± SE. *: P <0.05 indicates significant difference between adult and old women.
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In addition to glucose, lipids are another source of
energy in skeletal muscle. Several intracellular fatty acid-
binding proteins (FABP) have been identified. They have
important functions in the transport of intracellular fatty
acids by increasing their solubility and have been shown
to enhance the transport of fatty acids from the cell
membrane to the site of oxidation, i.e. the mitochondria,
and to the site of esterification into intramyocellular tri-
glycerol [69]. Muscle ageing was associated with the
down-regulation of heart FABP (FABP3, spot 2371), the
major FABP in skeletal muscle, and the up-regulation ofadipocyte FABP (FABP4, LIS-spot 3215). FABP3 plays an
important, but merely permissive role in fatty acid up-
take by skeletal muscles [70]. FABP4 is an adipocyte
marker, but is also expressed in muscle fibers [69].
Therefore, the age-related up-regulation of FABP4 may
relate to increased number of adipocytes, and/or to an
increased expression in muscle fibers. Except in our
shot-gun study [23], FABP4 was not noticed in previous
reports on sarcopenia. Of note, the lipid chaperone
FABP4 (also known as aP2) was also identified as a
predominant positive regulator of toxic lipid-induced
endoplasmic reticulum (ER) stress [71], and FABP4 up-
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muscle.
Overall, our proteomic analyses therefore provided
strong evidences for a decline in both glycolytic and mito-
chondrial energy metabolism in the old skeletal muscle.
Declines in mitochondrial oxidative capacity were pre-
viously reported with advancing age [11], although phy-
sical activity, rather than chronological age, was also
reported to be the primary determinant [72]. Because the
activity score was significantly higher for the adult than for
the old women group, future studies will be required to
specify whether mitochondrial oxidative capacity still de-
creases in old subjects maintaining physical activity scores.
Detoxification of cytotoxic products and cytoprotection in
the old muscle
Protection against mitochondrial oxidative stress
Mitochondrial dysfunctions may lead to an excessive pro-
duction of reactive oxygen species (ROS), and accumula-
ting evidences suggest that oxidative stress underlies the
ageing process in skeletal muscle [14]. The removal of
H2O2 in cells is mediated by catalase (CAT), glutathione
peroxidase and peroxiredoxin (PRDX) [73]. In the present
study, ageing of human skeletal muscle was associated
with lower levels of CAT (LIS-spot 1007) and higher levels
of PRDX3 (thioredoxin-dependent peroxide reductase,
LIS-spot 1754). Because CAT is localized preferentially in
peroxisomes [74], its function is limited to the inactivation
of H2O2 diffusing into these organelles. In contrast,
PRDX3 is the only peroxiredoxin restricted to mitochon-
dria, and high levels of PRDX3 may provide a primary line
of defence against H2O2 over-produced by the respiratory
chain in old muscle mitochondria. Neither CAT nor
PRDX3 have previously been reported in proteomic ana-
lyses of muscle ageing.
A wide range of activities have been reported for pro-
tein DJ-1 (PARK7, LIS-spot 1858), however, there is con-
sensus that PARK7 is responsive and protective against
mitochondrial oxidative stress [75]. PARK7 is an atypical
peroxiredoxin-like peroxidase [76]. During oxidative
attack, PARK7 is relocalized to mitochondria, has a
functional role in scavenging mitochondrial H2O2 and
decreases mitochondrial fragmentation [77]. Therefore
elevated levels of PARK7 in the old muscle may be im-
portant in regulating cellular antioxidant capacity.
Detoxification of cytotoxic products
Oxidative stress increases the production of cytotoxic
aldehydes, which can react with cellular proteins, nucleic
acids and cell membranes. Protection against reactive
aldehydes is provided by several families of detoxifica-
tion enzymes, including aldo-keto reductase (AKR) and
aldehyde dehydrogenase (ALDH). Our proteomic ana-
lysis provided evidences for perturbed scavenging ofreactive aldehyde products in the old muscle, as aldehyde
dehydrogenase (ALDH2, LIS-spot 1107) and alcohol de-
hydrogenase (AKR1A1, LIS-spot 1351), were up-regulated,
while aldose reductase (AKR1B1, spot 3328) and delta-
1-pyrroline-5-carboxylate dehydrogenase (ALDH4A1, LIS-
spot 1011) decreased with ageing. Similar regulations were
previously reported during ageing in rat skeletal muscle for
ALDH2 [15] and AKR1B1 [16,78]. However, no previous
study of muscle ageing has identified the differential ex-
pression of AKR1A1 and ALDH4A1.
The mitochondrial enzyme ALDH2 detoxifies aromatic
and aliphatic aldehydes (including 4-hydroxy-2-nonenal),
which are produced during oxidative stress as a result
of lipid peroxidation [79]. The cytosolic oxidoreductase
AKR1A1 has broad substrate specificity, and similarly cat-
alyzes the reduction of aliphatic and aromatic aldehydes,
ketones, and xenobiotics [80]. The up-regulations of
ALDH2 and AKR1A1 thus suggest enhanced scavenging
of reactive aldehyde products in the old skeletal muscle.
Our Western blot analyses confirmed that muscle ageing
is associated with higher levels of ALDH2 (Figure 6A).
While ALDH2 and AKR1A1 act principally as detoxifi-
cation enzymes, AKR1B1 and ALDH4A1 have additional
roles besides that of detoxification. Accumulating evidence
attributes a significant role to AKR1B1 in transducing
cytotoxic signals initiated by inflammatory cytokines [81].
AKR1B1 inhibitors have been reported to disrupt signal-
ling cascades leading to NFkB activation [82], and reduced
levels of AKR1B1 may therefore be important to limit acti-
vation of the NFkB pathway in the old muscle.
ALDH4A1 amino acid sequence diverges from the
other ALDH [83] and this enzyme is mostly involved in
metabolic regulation [84]. ALDH4A1 is metabolically
important, since its substrate (glutamic y-semialdehyde)
appears as a common intermediate in the degradative
and biosynthetic pathways of the amino acids arginine,
citrulline, ornithine and proline to and from glutamic
acid. The down regulation of ALDH4A1 may thus indi-
cate reduced intermediary metabolism in the old skeletal
muscle.
Quality control of cellular proteins
To detect, refold, and eventually eliminate abnormal
proteins, cells use quality control mechanisms that
buffer protein homeostasis (proteostasis) against cellular
stress. The proteomic analysis described here demon-
strated the differential regulation of 9 spots identified as
heat shock proteins (HSP). All were increased with age-
ing and they encompassed 3 HSP groups in human:
HSPA, HSPB and HSPC [85].
The small heat shock proteins (HSPB) are ATP-
independent chaperones. HSPBs prevent the aggregation
of improperly folded or partially denatured proteins, and
are involved in their transfer to the ATP-dependent
Figure 6 Examples of differential expression of proteins implicated in cytoprotection, cytodetoxification or proteolysis. Representative
sections of 2DGE images (left panel) and representative Western blots (right panel) for aldehyde dehydrogenase (ALDH2) (A), α-crystallin B chain
(HSPB5) (B), heat shock 70 kDa protein 1A/1B (HSPA1A) (C), HSP 90-beta (HSPC3) (D), and transitional endoplasmic reticulum ATPase (or valosin-
containing protein, VCP) (E). In each panel, histograms represent normalized volume of protein spot (n = 5–6), and Western blot quantification
(n = 7) for adult and old post-menopausal women. Results are indicated as means ± SE. *: P <0.05 indicates significant difference between adult
and old women.
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as proteasomes or autophagosomes [86]. Three HSPBs
displayed higher levels in old women compared to adult
women: heat shock protein beta-1 (HSPB1 or HSP27,
spots 1414 and 2375, and LIS-spots 1762 and 1763),
alpha-crystallin B chain (HSPB5 or CRYAB, LIS-spot
2356) and heat shock protein beta-6 (HSPB6 or HSP20,
LIS-spot 2364). Similar up-regulation of HSPB1, HSPB5
and HSPB6 have been previously reported for rat muscle
ageing [15,17,78,87]. Our Western blot experiments per-
formed with total muscle extracts confirmed that the old
human muscle exhibited higher levels of HSPB5 than
adult muscle (Figure 6B). In addition to chaperone acti-
vities, HSPB1 and HSPB5 have the ability to control the
redox status, protect the actin cytoskeleton [88] and in-
hibit apoptotic cell death [89].
The ATP-dependent chaperones of the HSPA group
(former HSP70) are essential for proteostasis as they con-
tribute to the folding and assembly of nascent poly-
peptides, the transport of proteins across membranes, and
the selection of misfolded proteins for degradation [90].
Muscle ageing was associated with the up-regulation of
two HSPA proteins: the heat shock 70 kDa protein 1A/1B
(HSPA1A or HSP70, spot 678), and the mitochondrial
stress-70 protein (HSPA9 or GRP75, spot 3332). None of
these HSPA have been previously reported in proteomic
analyses of muscle ageing, and our Western blot experi-
ments confirmed the age-related up-regulation of HSPA1A
(Figure 6C). HSPA1A is the most abundant inducible cyto-
protective HSP70 chaperone. Notably in rodents, over-
expression of HSPA1A has been repeatedly reported to
attenuate muscle atrophy induced by immobilization [91],
lengthening contractions [92] or cryo-lesions [93]. It is
therefore likely that the old human muscle may increase
HSPA1A levels as a protection against muscle atrophy.
HSPA9 is a central component of the mitochondrial pro-
tein import motor and it plays a key role in the folding of
matrix-localized mitochondrial proteins. HSPA9 is the only
known mitochondrial Hsp70 chaperone, and thus serves as
a unique scavenger of toxic protein aggregates in human
mitochondria [94].
One HSPC was further found to be up-regulated in
these ageing muscles: the heat shock protein HSP 90
(isoform alpha or beta, LIS-spot 755). HSP 90, which has
not been identified in previous muscle ageing studies, is
another important chaperone that functions downstream
of HSPA in the ATP-dependent folding and confor-
mational regulation of many client proteins, including
protein kinases, steroid receptors, endothelial NO syn-
thase and transcription factors [95]. Most of the clients,
with which HSP 90 interacts, are thus involved in signal
transduction, making HSP 90 a critical factor in cell sig-
nalling. Western blot experiments confirmed the age-
related up-regulation of HSP 90-beta (HSPC3, Figure 6D).Finally and in addition to the HSP proteins, the cha-
perone operating in the endoplasmic reticulum (ER),
protein disulfide-isomerase A3 (PDIA3, LIS-spot 1081),
was also found to increase with human muscle ageing,
and this observation is in agreement with previous stu-
dies in rat [15,96]. PDIA3 is a multifunctional protein with
thiol-protein disulphide oxidoreductase activity, which en-
sures proper folding of glycoproteins and assembly of
major histocompatibility complex class I complex [97].
Outside the ER, PDIA3 also functions as a plasma mem-
brane receptor for 1α,25-dihydroxy vitamin D3 [98],
which might be important with regard to the implication
of Vitamin D in ageing [99].
Cytoprotection in the old skeletal muscle
In agreement with a previous study in rat [78], higher
levels of two isoforms of carbonic anhydrase 2 (CA2,
spot 3289 and LIS-spot 812) were identified in senescent
human muscle. No consensus has been reached in the
literature about CA3, as both increased [16,21] and de-
creased levels [11,17] were observed in old muscles. Our
analyses of muscle ageing in women indicated an over-
expression of 2 isoforms of CA3 (LIS-spots 1752 and
1755) and this was confirmed by our shot-gun study
[23]. The various isoforms of CAs play a crucial role
in CO2-removal and CO2-provision for metabolic pro-
cesses, and are central for the acid–base balance and the
regulatory processes of ion homeostasis. Numerous pro-
teins are involved in ion homeostasis, including the
selenium-binding protein 1 (SELENBP1) of which two
isoforms were increased (LIS-spots 1119 and 1127) and
one isoform was decreased (spot 877) in ageing.
Proteolytic systems
Muscle proteins are continuously turning over, and cells
contain multiple proteolytic systems to carry out the deg-
radation process. Several components of the major proteo-
lytic systems, i.e. ubiquitin-proteasome [100] and lysosomal
autophagy [101,102], were in the present study differen-
tially regulated with ageing in human skeletal muscle. The
old muscle thus exhibited higher levels of the ubiquitin-
like modifier activating enzyme 1 (UBA1, LIS-spot 3614),
and transitional endoplasmic reticulum ATPase (or valo-
sin-containing protein, VCP, LIS-spot 3654), while the
proteasome subunit beta type-4 (PSMB4, spot 2410), UV
excision repair protein RAD23 homolog A (RAD23A, spot
3387) and mitochondrial elongation factor Tu (TUFM,
spot 3270) were down-regulated during ageing.
The VCP ATPase binds multiple ubiquitin ligases and
ubiquitinated proteins and triggers extraction of client
proteins from complexes or cellular surfaces, often to
facilitate degradation by the proteasome [103]. VCP is
thus central for the extraction and degradation of mis-
folded endoplasmic reticulum-associated (ERAD) [104]
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involved in a wide variety of cellular processes, such as
DNA repair [106], myofibril biogenesis [107], membrane
fusion [108], autophagosome maturation [109] and mito-
phagy [110]. The up-regulation of VCP in skeletal muscle
of old women was confirmed by Western-blot analysis
(Figure 6E), and is in agreement with previous observa-
tions in rat muscle [111]. The scaffold protein RAD23A,
which was originally identified as an important factor in-
volved in the recognition of DNA lesions [112], also serves
as an ubiquitin receptor and plays a central role in
targeting polyubiquitynated proteins, including ERAD
substrates, for proteasomal degradation [113]. TUFM is
important to deliver aminoacyl-tRNA to mitochondrial
ribosome, and also promotes autophagy by interac-
ting with autophagy-related proteins ATG12–ATG5 and
ATG16L1 [114].
In addition to intracellular proteolysis, proteomics ana-
lysis of muscle ageing identified an up-regulation of the
Xaa-Pro dipeptidase (PEPD, LIS-spot 1088), an extracellular
proteinase which specifically splits iminodipeptides with
C-terminal proline or hydroxyproline. Because of the high
level of iminoacids in collagen, PEPD seems to be im-
portant for extracellular matrix remodeling [115]. At the
extracellular level, we also found that muscle ageing was as-
sociated with lower level of anti-thrombin III (SERPINC1,
LIS-spot 1014), which belongs to the family of serine prote-
ase inhibitors.
With the exception of VCP [111], none of these poten-
tial proteolysis biomarkers has previously been men-
tioned in any proteomic study on muscle ageing.
Serum and transport proteins
Several spots were identified as differentially expressed
plasma transport proteins. A number of these proteins
were found decreased in aged muscle, including vitamin
D binding protein (GC, LIS-spot 1070), transthyretin
(TTR, LIS-spot 2892) and apolipoprotein A-I (APOA1,
LIS-spots 1847, 1855 and 3624). Vitamin D binding
protein is a major plasma transport protein for vitamin D,
while TTR transports thyroxine (T4) and retinol (vita-
min A) through the association with retinol-binding
protein. As a major component of the high density lipo-
protein complex, APOA1 helps to clear fats, inclu-
ding cholesterol, from peripheral tissues. APOA1 is also
partly localized on skeletal muscle lipid droplets [116].
In contrast, serotransferrin (TF, LIS-spot 681), which
controls level of iron and oxidative stress by increasing
iron uptake, was up-regulated in aged muscle. Another
serum protein, fibrinogen gamma chain (FGG, spot
919), was decreased during ageing. Altered levels of
serum proteins may be related to impaired blood-flow
distribution that has been reported in aged muscle
fibers [117].Miscellaneous
Two isoforms of the ES1 protein homolog (C21orf33,
spots 1429, 1430) also decreased in aged muscle. C21orf33
(also known as KNP1) is ubiquitously expressed but
strongly so in heart and skeletal muscle and potential
mitochondrial targeting signals were found in this protein
[118], but its actual physiologic function is not known.
Cytosolic 5'-nucleotidase 3 (NT5C3A, spot 1177) mainly
catalyzes the dephosphorylation of pyrimidine nucleoside
monophosphates, and therefore plays an important role in
both endogenous nucleoside and nucleotide pool balance
[119]. The age-related down-regulation of NT5C3A (−1.6
fold) that we observed in senescent women has not been
previously reported in the literature. Finally, spot 1429
decreased 1.2-fold and is identified as apolipoprotein B
mRNA-editing enzyme, catalytic polypeptide-like 2 (APO-
BEC2) that belongs to the cytidine deaminase superfamily
and mediates editing of mRNA. Interestingly, APOBEC2
deficiency in mice has recently been associated with a shift
to a slow-fiber type in muscle, and with diminished body
mass and mild myopathy [120].
Conclusions
To conclude, our proteomics analyses has resulted in the
identification of numerous proteins whose expression is
dysregulated in old skeletal muscle. To our knowledge,
this is the most extensive proteomic study of muscle age-
ing in humans. All these proteins have been classified into
seven major groups, associated with myofilaments and
cytoskeleton, energy metabolism, detoxification, cytopro-
tection, signal transduction, proteostasis and proteolysis,
and Figure 7 summarizes the functional interaction net-
works linking the differentially expressed proteins. Many
of the candidate proteins identified in this study by diffe-
rential proteomics were previously unrecognized (34 out
of 67) in previous ageing studies of skeletal muscle, in par-
ticular for proteins implicated in cytoprotection, signal
transduction or proteolysis. By comparing adult and old
post-menopausal women, we have identified a group of
proteins in old skeletal muscle, which indicates potential
mechanisms of ageing and may lead to the development
of new biomarkers of sarcopenia and novel targets for
therapeutic intervention.
Methods
Subjects
Subjects were admitted to the Leiden University Medical
Center (Leiden, The Netherlands) and Rijnland Hospital
(Leiderdorp, The Netherlands) between June 2010 and
September 2012. Exclusion criteria consisted of previous
knee or hip surgery (with the exception of arthroscopy),
rheumatoid disease, diabetes mellitus, use of oral corti-
costeroids, and metastasized malignancy. Twenty four
post-menopausal women undergoing elective hip surgery
Figure 7 STRING interaction network showing the association between differentially expressed proteins in old post-menopausal
women compared to adult women. The interaction map was generated using STRING [123] and default settings (Medium confidence of 0.4
and 4 criteria for linkage: co-expression, experimental evidences, existing databases and text mining). The proteins names used in this network
are listed in Tables 1 and 2.
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divided in two groups: adult women aged 56.4 ± 1.3
years (n = 11; age range 48–61 years) and old women
aged 78.3 ± 0.5 years (n = 13; age range 76–82 years). We
limited our study to post-menopausal women in order
to avoid potential side effects of the menstrual hormone
cycle. The study was approved by the medical ethical
committees (P10.060 - HEALTH-2007-2.4.5-10: Under-
standing and combating age related muscle weakness
“MYOAGE”) of the Leiden University Medical Center and
Rijnland Hospital, and was performed in accordance with
the principles of the revised Declaration of Helsinki. Writ-
ten informed consent was obtained from all patients. The
adult subjects were more active than elderly, but not in-
volved in any specific training program. The activity score,
based on self-report in a questionnaire, was significantly
higher for adult than for old women (P <0.035). Adult
women were cycling more than old women (83% and
36%, respectively), and adult women used less walking aid
than old women (33% vs. 71%). The adult and old groups
presented similar body weight (69.0 + 12.9 kg and 75.5 +12.5 kg, respectively), height (168 + 8 cm and 166 + 7 cm,
respectively) and body mass index. Muscle samples were
obtained by surgical biopsy from the vastus lateralis
muscle and were immediately frozen in liquid nitrogen
and stored at −80°C until used.
Reagents
Acrylamide, bisacrylamide and Hybond™-P membrane
were purchased from Amersham Bioscience/GE Health-
care (Little Chalfont, UK). IPG buffers, 18 cm ReadyStrip
IPG strips (pH 5–8), 18 cm ReadyStrip IPG strips (pH
3.0-5.6), 18 cm ReadyStrip IPG strips (pH 5.3-6.5), and
Electrode Wicks were from Bio-Rad Laboratories (Marnes
la Coquette, France), and orthophosphoric acid, am-
monium sulphate and absolute ethanol were from VWR
(Strasbourg, France). All other chemicals were from Sigma
(L’Isle-d’Abeau Chesnes, France). Sequence grade-modified
trypsin was purchased from Promega (Charbonnières-les-
bains, France), and Luminata™ Western Horseradish pero-
xidase (HRP) substrate and ReBlot Plus Strong antibody
stripping solution were from Millipore (Molsheim, France).
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VCL and FHL3 were from Sigma. The anti-mouse IgG-
HRP, anti-rabbit IgG-HRP, anti-SRL and anti-β-actin
(ACTB) were from Santa-Cruz biotechnology (Heidelberg,
Germany). The polyclonal antibodies against GPD1,
MYOZ1, ANXA1, ANXA5, GSTO1, HSPB5, HSPC3,
ALDH2, NDUFS2, UQCRFS1, ENO3, HSPA1A and
VCP were purchased from Euromedex (Genetex,
Souffelweyersheim, France).
Protein extraction
Total muscle extracts and LIS extracts were prepared for
each subject, and each individual was assessed separately.
For total muscle extracts, biopsies of vastus lateralismuscle
were from twelve post-menopausal women divided in two
groups: adult control (n = 5) and aged (n = 7). Muscle ali-
quots were homogenized (40 mg/ml) in a solubilisation
buffer containing 8.3 M urea, 2 M thiourea, 2% (w/v)
CHAPS, 1% (v/v) dithiothreitol, and 2% (v/v) IPG buffer
pH 3–10 using a TissueRuptor (Qiagen, Courtaboeuf,
France), shaken for 30 min on ice and centrifuged for 30
min at 10,000 X g. The supernatants were aliquoted and
stored at −20°C until analysis. Protein concentration, de-
termined using the Bradford assay system (Bio-Rad), was
7.2 ± 1.1 mg/ml and 5.5 ± 1.2 mg/ml for the adult and old
group, respectively.
LIS extracts were prepared from muscle biopsies of
twelve post-menopausal women, either adult (n = 6) or
aged (n = 6), according to Sayd et al. [121]. Briefly, fro-
zen muscle was homogenized using a TissueRuptor in
40 mM Tris (pH 7.0), 2 mM EDTA, and protease inhibi-
tor cocktail (Sigma). After centrifugation at 4°C for 10
min at 10,000 X g, the supernatant, referred to as LIS
extract, was stored at −80°C. Protein concentration was
9.3 ± 2.2 mg/ml and 9.4 ± 1.6 mg/ml for the adult and
old group, respectively.
Two-dimensional gel electrophoresis
For total muscle extracts, 700 μg protein were separated
per gel using IPG strips of three different pH ranges (pH
3.0-5.6, pH 5.3-6.5 and pH 5–8) for each individual. For
isoelectrofocusing, samples were diluted with rehydration
buffer containing 8.3 M urea, 1 M thiourea, 2% (w/v)
CHAPS, 0.28% (v/v) dithiothreitol, 2% (v/v) IPG buffer
(pH 3–10), and 0.01% (w/v) Coomassie Brilliant blue
R-250. The IPG strips were passively rehydrated with
330 μl of this solution for 16 h under mineral oil in the
PROTEAN IEF Cell system (Bio-Rad) at 20°C, and actively
rehydrated using Electrode Wicks loaded onto IPG strips
for 6 h at 50 V. During active rehydration, Electrode
Wicks were changed every 2 h. Isolectrofocusing was then
performed at 0.05 mA per IPG strip at 50 V for 2 h, 200 V
for 1 h, 500 V for 1 h, 1000 V for 2 h, 8000 V for 6 h and
finally 8000 V to achieve 46,000 Vh.For LIS extracts, gels were made in triplicate for each
individual and 700 μg protein was analyzed per gel. The
IPG strips (pH 5–8) were passively and actively rehy-
drated as described above and isolectrofocusing was per-
formed at 0.05 mA per IPG strip at 50 V for 1 h, 250 V
for 1 h, 500 V for 1 h, 1000 V for 2 h, 1000 V for 1 h,
8000 V for 7 h and finally 8000 V to achieve 60,000 Vh.
The strips were then equilibrated twice for 15 min
with gentle shaking in equilibration buffer containing 6
M urea, 50 mM Tris–HCl buffer (pH 8.8), 30% (v/v)
glycerol, 2% (w/v) SDS. DTT (1% w/v) was added to the
first, and iodoacetamide (5% w/v) to the second equi-
libration buffer. Separation of proteins, according to
molecular weight, was carried out using a Protean Plus
DodecaCell system (Bio-Rad) on homogenous 20 cm
polyacrylamide gels (11% T, 2.6% C). The equilibrated
strips were sealed to the top of the horizontal gel with
agarose and subjected to 50 V for 1 h followed by 9 mA
per gel until the blue dye reached the bottom of the gel.
Visualization of proteins and image analysis
2DGE were fixed overnight in a solution containing 30%
(v/v) ethanol and 2% (v/v) orthophosphoric acid, washed
twice for 30 min in 2% (v/v) orthophosphoric acid and
then transferred to a solution containing 18% (v/v) etha-
nol, 2% (v/v) orthophosphoric acid and 15% (v/v) am-
monium sulphate for 30 min. The gels were stained for
72 h with 0.06% (w/v) Coomassie Blue G-250 added to
this last solution. Gels were scanned using the ImageScan-
ner and LabScan-v.5 software (Amersham Bioscience) and
protein spots were analyzed and matched between all gels
using Progenesis SameSpot software (Non Linear Dynam-
ics, Newcastle upon Tyne, UK). Age effect was evaluated
for normalized volumes of 2DGE spots using an unpaired
Student’s t test procedure with significance set at P <0.05.
The numbers of biological replicates (5–7) that we used in
the present study is similar to those used in previous
investigations [20,21]. Throughout the manuscript, we
qualified the differential spots as “potential” biomarkers,
being aware that any list of candidate identified in a dis-
covery stage must be validated in other large and inde-
pendent cohort of subjects.
Protein identification by mass spectrometry
Proteins with significant changed abundance were picked
for tryptic digestion from gels. Excised protein spots from
2DGE were destained with 25 mM ammonium bicarbo-
nate, 5% (v/v) acetonitrile for 30 min and twice in 25 mM
ammonium bicarbonate, 50% (v/v) acetonitrile for 30 min
each. Protein spots were then dehydrated using 100%
acetonitrile for 10 min and dried in a vacuum SpeedVac.
Proteins were digested overnight at 37°C using 12.5 ng/μl
of sequence grade-modified trypsin (Promega) in 25 mM
ammonium bicarbonate. Peptide extraction was optimised
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sonication.
After concentration in the SpeedVac, the peptides mix-
tures were analyzed by nano-LC-MS/MS using an Ultimate
3000 system (Dionex, Voisins le Bretonneux, France)
coupled to an LTQ-Velos mass spectrometer (Thermo
Fisher Scientific, Bremen, Germany). Eight microliters of
each peptide sample were loaded on a C18 pre-column
(300-μm inner diameter × 5 mm; Dionex) at 20 μl/min in
5% acetonitrile, 0.05% trifluoroacetic acid. After 6 min of
desalting, the pre-column was switched on line with the
analytical C18 column (75-μm inner diameter × 15 cm;
PepMap C18, Dionex) equilibrated in 96% solvent A (0.5%
formic acid) and 4% solvent B (80% acetonitrile, 0.5% for-
mic acid). Peptides were eluted using a 4-50% gradient of
solvent B during 30 min at a 300 nl/min flow rate. The elu-
ate was electrosprayed into the mass spectrometer through
a nano-electrospray ion source. The LTQ-Velos was oper-
ated in a CID top 10 mode (1 full scan MS and the 10
major peaks in the full scan are selected for MS/MS). The
Mascot Daemon software (version 2.3.2; Matrix Science,
London, UK) was used to perform database searches, using
the Thermo Proteome Discoverer v1.3 with default para-
meters to generate peak lists.
For protein identification, the UniP Human database
(2012/11, 86675 seq) was used. Peptide mass tolerance
was set to 1.5 Da and fragment mass tolerance was set
to 0.8 Da. Two missed cleavages were allowed, and vari-
able modifications were methionine oxidation and carba-
midomethylation of cysteine. Identification results were
imported and filtered by Proteome Discoverer. Protein
identification was validated when at least three unique
peptides originating from one protein showed significant
identification Mascot scores (P <0.05) with False Discovery
Rate (FDR < 5%) automatically calculated by Proteome
Discoverer. When redundancy occurs, Proteome Discover
uses principles of parsimony to give unambiguous identifi-
cation of an isoform of a protein. This was not possible for
only 2 spots (LIS spots 1210 and 755), for which we indi-
cate the two isoforms in Table 2. In the present study we
considered that proteins validated for the entire number
of spots analysed were really present on the basis of Mas-
cot score, percentage of sequence coverage of the entire
protein, peptide spectrum matches, unique peptides re-
lated to each protein isoform/member, and MW agree-
ments. The mass spectrometry proteomics data have been
deposited to the ProteomeXchange Consortium [122] via
the PRIDE partner repository with the dataset identifier
PXD001527.
Immunoblotting
For Western-Blot analysis, total protein extracts were re-
solved by sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis, electrotransferred to Hybon™-P membrane andprobed with anti-VCL, anti-FHL3, anti-SRL, anti-MYOZ1,
anti-ANXA1, anti-ANXA5, anti-GSTO1, anti-ENO3, anti-
GPD1, anti-UQCRFS1, anti-NDUFS2, anti-ALDH2, anti-
HSPB5, anti-HSPA1A, anti-HSPC3, or anti-VCP. Primary
antibodies were resolved with corresponding horseradish
peroxidase-linked goat anti-mouse or anti-rabbit secon-
dary antibodies, and immunoreactive proteins were de-
tected using enhanced chemiluminescence and a Charge
Coupled Device camera (GBOX, Syngene, Cambridge,
UK). Each blot was dehybridized using 1X ReBlot Plus
Strong antibody stripping solution and probed with anti-
ACTB for normalization. To determine the significance of
ageing, a Student’s t test was used with significance set at
P <0.05; results are expressed as the mean ± standard
deviation.
Functional correlation and pathway analysis
Pathway analysis was performed using the Search Tool for
the Retrieval of INteracting Genes (String) 9.0 database
(http://string-db.org) [123]. String analysis options were
based on ‘evidence’ mode, we did not add or remove any
protein partners, and we used clustering by K means to
reveal sub-grouping within the network.
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